These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36134953)

  • 21. Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency.
    Mariotti S; Capocefalo A; Chiantore MV; Iacobino A; Teloni R; De Angelis ML; Gallinaro A; Pirillo MF; Borghi M; Canitano A; Michelini Z; Baggieri M; Marchi A; Bucci P; McKay PF; Acchioni C; Sandini S; Sgarbanti M; Tosini F; Di Virgilio A; Venturi G; Marino F; Esposito V; Di Bonito P; Magurano F; Cara A; Negri D; Nisini R
    Front Immunol; 2021; 12():750386. PubMed ID: 34764961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern.
    Wu D; Cong J; Wei J; Hu J; Sun W; Ran W; Liao C; Zheng H; Ye L
    Int J Nanomedicine; 2023; 18():5781-5795. PubMed ID: 37869063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.
    Tatham L; Kipar A; Sharp J; Kijak E; Herriott J; Neary M; Box H; Gallardo Toledo E; Valentijn A; Cox H; Pertinez H; Curley P; Arshad U; Rajoli RKR; Rannard S; Stewart JP; Owen A
    Microbiol Spectr; 2024 Aug; 12(8):e0391623. PubMed ID: 39012120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy.
    Chiang CY; Chen MY; Hsu CW; Liu CY; Tsai YW; Liao HC; Yan JY; Chuang ZS; Wang HI; Pan CH; Yu CY; Yu GY; Liao CL; Liu SJ; Chen HW
    J Biomed Sci; 2022 Jun; 29(1):37. PubMed ID: 35681239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced Omicron Variant Neutralization by a Human Antibody Tailored to Wild-Type and Delta-Variant SARS-CoV-2 RBDs.
    Lee J; Kim B; Woo HM; Kim JW; Jung I; Park SW; Kim YS; Na JH; Jung ST
    Mol Pharm; 2024 Sep; 21(9):4336-4346. PubMed ID: 39058261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a neutralization monoclonal antibody with a broad neutralizing effect against SARS-CoV-2 variants.
    Ko HL; Lee DK; Kim Y; Jang HJ; Lee YW; Lee HY; Seok SH; Park JW; Limb JK; On DI; Yun JW; Lyoo KS; Song D; Yeom M; Lee H; Seong JK; Lee S
    Virol J; 2023 Dec; 20(1):285. PubMed ID: 38041113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants.
    Sun CP; Chiu CW; Wu PY; Tsung SI; Lee IJ; Hu CW; Hsu MF; Kuo TJ; Lan YH; Chen LY; Ng HY; Chung MJ; Liao HN; Tseng SC; Lo CH; Chen YJ; Liao CC; Chang CS; Liang JJ; Draczkowski P; Puri S; Chang YC; Huang JS; Chen CC; Kau JH; Chen YH; Liu WC; Wu HC; Danny Hsu ST; Wang IH; Tao MH
    Mol Ther; 2023 Nov; 31(11):3322-3336. PubMed ID: 37689971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants.
    Chang MR; Ke H; Coherd CD; Wang Y; Mashima K; Kastrunes GM; Huang CY; Marasco WA
    EBioMedicine; 2022 Jun; 80():104025. PubMed ID: 35533497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct in vitro and in vivo neutralization profiles of monoclonal antibodies elicited by the receptor binding domain of the ancestral SARS-CoV-2.
    Kwon HJ; Zhang J; Kosikova M; Tang W; Ortega-Rodriguez U; Peng H; Meseda CA; Pedro CL; Schmeisser F; Lu J; Kang I; Zhou B; Davis CT; Wentworth DE; Chen WH; Shriver MC; Barnes RS; Pasetti MF; Weir JP; Chen B; Xie H
    J Med Virol; 2023 Mar; 95(3):e28673. PubMed ID: 36916782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents.
    Wang Z; Li D; Chen Y; Sun Y; Jin C; Hu C; Feng Y; Su J; Ren L; Hao Y; Wang S; Zhu M; Liu Y; Qi J; Zhu B; Shao Y
    Front Immunol; 2023; 14():1160283. PubMed ID: 37234155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
    Rao X; Zhao R; Tong Z; Guo S; Peng W; Liu K; Li S; Wu L; Tong J; Chai Y; Han P; Wang F; Jia P; Li Z; Zhao X; Li D; Zhang R; Zhang X; Zou W; Li W; Wang Q; Gao GF; Wu Y; Dai L; Gao F
    Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2314193120. PubMed ID: 38109549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential Outcomes of Infection by Wild-Type SARS-CoV-2 and the B.1.617.2 and B.1.1.529 Variants of Concern in K18-hACE2 Transgenic Mice.
    He Y; Henley J; Sell P; Comai L
    Viruses; 2023 Dec; 16(1):. PubMed ID: 38257760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
    O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
    Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor.
    Andrade SA; Batalha-Carvalho JV; Curi R; Wen FH; Covas DT; Chudzinski-Tavassi AM; Moro AM
    Front Immunol; 2022; 13():871874. PubMed ID: 35898497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivated whole virion vaccine protects K18-hACE2 Tg mice against the Omicron SARS-CoV-2 variant via cross-reactive T cells and nonneutralizing antibody responses.
    Kruglov AA; Bondareva MA; Gogoleva VS; Semin IK; Astrakhantseva IV; Zvartsev R; Lunin AS; Apolokhov VD; Shustova EY; Volok VP; Ustyugov AA; Ishmukhametov AA; Nedospasov SA; Kozlovskaya LI; Drutskaya MS
    Eur J Immunol; 2024 Mar; 54(3):e2350664. PubMed ID: 38088236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination.
    Chi X; Guo Y; Zhang G; Sun H; Zhang J; Li M; Chen Z; Han J; Zhang Y; Zhang X; Fan P; Zhang Z; Wang B; Zai X; Han X; Hao M; Fang T; Xu J; Wu S; Chen Y; Fang Y; Dong Y; Sun B; Zhang J; Li J; Zhao G; Yu C; Zhou Q; Chen W
    Signal Transduct Target Ther; 2022 Apr; 7(1):139. PubMed ID: 35478188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
    Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
    mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
    Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
    J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.